124 related articles for article (PubMed ID: 31463908)
61. ADAMTS-9 in Mouse Cartilage Has Aggrecanase Activity That Is Distinct from ADAMTS-4 and ADAMTS-5.
Rogerson FM; Last K; Golub SB; Gauci SJ; Stanton H; Bell KM; Fosang AJ
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30699963
[TBL] [Abstract][Full Text] [Related]
62. A microplate assay for the screening of ADAMTS-4 inhibitors.
Thomas M; Sabatini M; Bensaude F; Mignard B; Ortuno JC; Caron I; Boutin JA; Ferry G
Matrix Biol; 2006 May; 25(4):261-7. PubMed ID: 16442274
[TBL] [Abstract][Full Text] [Related]
63. Catabolism of aggrecan, decorin and biglycan in tendon.
Rees SG; Flannery CR; Little CB; Hughes CE; Caterson B; Dent CM
Biochem J; 2000 Aug; 350 Pt 1(Pt 1):181-8. PubMed ID: 10926842
[TBL] [Abstract][Full Text] [Related]
64. ADAMTS and ADAM metalloproteinases in osteoarthritis - looking beyond the 'usual suspects'.
Yang CY; Chanalaris A; Troeberg L
Osteoarthritis Cartilage; 2017 Jul; 25(7):1000-1009. PubMed ID: 28216310
[TBL] [Abstract][Full Text] [Related]
65. A quantitative assay for aggrecanase activity.
Will H; Dettloff M; Bendzkô P; Sveshnikov P
J Biomol Tech; 2005 Dec; 16(4):459-72. PubMed ID: 16522869
[TBL] [Abstract][Full Text] [Related]
66. Effects of ceramide on aggrecanase activity in rabbit articular cartilage.
Sabatini M; Thomas M; Deschamps C; Lesur C; Rolland G; de Nanteuil G; Bonnet J
Biochem Biophys Res Commun; 2001 May; 283(5):1105-10. PubMed ID: 11355886
[TBL] [Abstract][Full Text] [Related]
67. Matrix metalloproteinases are involved in C-terminal and interglobular domain processing of cartilage aggrecan in late stage cartilage degradation.
Little CB; Hughes CE; Curtis CL; Janusz MJ; Bohne R; Wang-Weigand S; Taiwo YO; Mitchell PG; Otterness IG; Flannery CR; Caterson B
Matrix Biol; 2002 Apr; 21(3):271-88. PubMed ID: 12009333
[TBL] [Abstract][Full Text] [Related]
68. Cleavage of aggrecan at the Asn341-Phe342 site coincides with the initiation of collagen damage in murine antigen-induced arthritis: a pivotal role for stromelysin 1 in matrix metalloproteinase activity.
van Meurs J; van Lent P; Stoop R; Holthuysen A; Singer I; Bayne E; Mudgett J; Poole R; Billinghurst C; van der Kraan P; Buma P; van den Berg W
Arthritis Rheum; 1999 Oct; 42(10):2074-84. PubMed ID: 10524678
[TBL] [Abstract][Full Text] [Related]
69. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro.
Stanton H; Rogerson FM; East CJ; Golub SB; Lawlor KE; Meeker CT; Little CB; Last K; Farmer PJ; Campbell IK; Fourie AM; Fosang AJ
Nature; 2005 Mar; 434(7033):648-52. PubMed ID: 15800625
[TBL] [Abstract][Full Text] [Related]
70. The effect of protease inhibitors on the induction of osteoarthritis-related biomarkers in bovine full-depth cartilage explants.
He Y; Zheng Q; Jiang M; Sun S; Christiansen TG; Kassem M; Karsdal MA; Bay-Jensen AC
PLoS One; 2015; 10(4):e0122700. PubMed ID: 25909781
[TBL] [Abstract][Full Text] [Related]
71. Matrix metalloproteinase digestion of aggrecan in human cartilage tumours.
Toriyama M; Rosenberg AE; Mankin HJ; Fondren T; Treadwell BV; Towle CA
Eur J Cancer; 1998 Nov; 34(12):1969-73. PubMed ID: 10023324
[TBL] [Abstract][Full Text] [Related]
72. Oncostatin M in combination with tumour necrosis factor {alpha} induces a chondrocyte membrane associated aggrecanase that is distinct from ADAMTS aggrecanase-1 or -2.
Hui W; Barksby HE; Young DA; Cawston TE; McKie N; Rowan AD
Ann Rheum Dis; 2005 Nov; 64(11):1624-32. PubMed ID: 15883123
[TBL] [Abstract][Full Text] [Related]
73. A contentious issue finds some clarity: on the independent and complementary roles of aggrecanase activity and MMP activity in human joint aggrecanolysis.
Sandy JD
Osteoarthritis Cartilage; 2006 Feb; 14(2):95-100. PubMed ID: 16257242
[TBL] [Abstract][Full Text] [Related]
74. Antibody-based exosite inhibitors of ADAMTS-5 (aggrecanase-2).
Santamaria S; Yamamoto K; Botkjaer K; Tape C; Dyson MR; McCafferty J; Murphy G; Nagase H
Biochem J; 2015 Nov; 471(3):391-401. PubMed ID: 26303525
[TBL] [Abstract][Full Text] [Related]
75. The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis.
Lohmander LS; Neame PJ; Sandy JD
Arthritis Rheum; 1993 Sep; 36(9):1214-22. PubMed ID: 8216415
[TBL] [Abstract][Full Text] [Related]
76. Aggrecanase-mediated cartilage degradation.
Arner EC
Curr Opin Pharmacol; 2002 Jun; 2(3):322-9. PubMed ID: 12020478
[TBL] [Abstract][Full Text] [Related]
77. Calcium pentosan polysulfate inhibits the catabolism of aggrecan in articular cartilage explant cultures.
Munteanu SE; Ilic MZ; Handley CJ
Arthritis Rheum; 2000 Oct; 43(10):2211-8. PubMed ID: 11037880
[TBL] [Abstract][Full Text] [Related]
78. Matrix metalloproteinase 17 is necessary for cartilage aggrecan degradation in an inflammatory environment.
Clements KM; Flannelly JK; Tart J; Brockbank SM; Wardale J; Freeth J; Parker AE; Newham P
Ann Rheum Dis; 2011 Apr; 70(4):683-9. PubMed ID: 21216815
[TBL] [Abstract][Full Text] [Related]
79. Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification.
Larkin J; Lohr TA; Elefante L; Shearin J; Matico R; Su JL; Xue Y; Liu F; Genell C; Miller RE; Tran PB; Malfait AM; Maier CC; Matheny CJ
Osteoarthritis Cartilage; 2015 Aug; 23(8):1254-66. PubMed ID: 25800415
[TBL] [Abstract][Full Text] [Related]
80. Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine.
Sandy JD; Gamett D; Thompson V; Verscharen C
Biochem J; 1998 Oct; 335 ( Pt 1)(Pt 1):59-66. PubMed ID: 9742213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
